In this issue:
ORIOLE shows SABR is effective for metastases-directed therapy in oligometastatic prostate cancer
EFS cannot be used as a surrogate for OS in men with localized prostate cancer treated with radiation
Efficacy of hormone treatment is significantly impacted by post-prostatectomy PSA levels
Salvage ipilimumab and nivolumab in patients with metastatic RCC after prior immune checkpoint inhibitors
Post-platinum switch maintenance with immune checkpoint blockade shows promise in metastatic UC
Efficacy of immune checkpoint inhibitor therapy is not compromised in patients with variant UC
Molecular subtyping to predict outcome following neoadjuvant pembrolizumab in bladder cancer
Neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma
Please login below to download this issue (PDF)